This, in conjunction with lower fasting blood glucose and improved glucose tolerance, suggests that GCK overexpression reduced the HFD-stimulated compensatory increase in β-cell area, similar to what was previously proposed for a glucokinase activator (GKA) (Nakamura et al., 2009). The gene discussed is GCK; the disease is glucose measurement.